Insulin requires normal expression and signaling of insulin receptor A to reverse gestational diabetes-reduced adenosine transport in human umbilical vein endothelium

FASEB J. 2015 Jan;29(1):37-49. doi: 10.1096/fj.14-254219. Epub 2014 Oct 28.

Abstract

Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Insulin receptors A (IR-A) and B (IR-B) are expressed in HUVECs, and GDM results in higher IR-A mRNA expression vs. cells from normal pregnancies. We studied whether the reversal of GDM effects on transport by insulin depends on restoration of IR-A expression. We specifically measured hENT1 expression [mRNA, protein abundance, SLC29A1 (for hENT1) promoter activity] and activity (adenosine transport kinetics) and the role of IR-A/IR-B expression and signaling [total and phosphorylated 42 and 44 kDa mitogen-activated protein kinases (p44/42(mapk)) and Akt] in IR-A, IR-B, and IR-A/B knockdown HUVECs from normal (n = 33) or GDM (n = 33) pregnancies. GDM increases IR-A/IR-B mRNA expression (1.8-fold) and p44/42(mapk):Akt activity (2.7-fold) ratios. Insulin reversed GDM-reduced hENT1 expression and maximal transport capacity (V(max)/K(m)), and GDM-increased IR-A/IR-B mRNA expression and p44/42(mapk):Akt activity ratios to values in normal pregnancies. Insulin's effect was abolished in IR-A or IR-A/B knockdown cells. Thus, insulin requires normal IR-A expression and p44/42(mapk)/Akt signaling to restore GDM-reduced hENT1 expression and activity in HUVECs. This could be a protective mechanism for the placental macrovascular endothelial dysfunction seen in GDM.

Keywords: endothelial dysfunction; human placenta; nucleoside membrane transport.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / metabolism*
  • Adolescent
  • Adult
  • Antigens, CD / genetics
  • Antigens, CD / metabolism*
  • Biological Transport, Active
  • Case-Control Studies
  • Diabetes, Gestational / genetics
  • Diabetes, Gestational / metabolism*
  • Equilibrative Nucleoside Transporter 1 / genetics
  • Equilibrative Nucleoside Transporter 1 / metabolism
  • Female
  • Gene Expression
  • Gene Knockdown Techniques
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Infant, Newborn
  • Insulin / metabolism*
  • Kinetics
  • MAP Kinase Signaling System
  • Male
  • Pregnancy
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptor, Insulin / antagonists & inhibitors
  • Receptor, Insulin / genetics
  • Receptor, Insulin / metabolism*
  • Signal Transduction
  • Umbilical Veins / metabolism
  • Young Adult

Substances

  • Antigens, CD
  • Equilibrative Nucleoside Transporter 1
  • Insulin
  • RNA, Messenger
  • SLC29A1 protein, human
  • INSR protein, human
  • Receptor, Insulin
  • Proto-Oncogene Proteins c-akt
  • Adenosine